Trial | NCT00485108  Report issue

Title

Anti-inflammatory Therapy Following Selective Laser Trabeculoplasty
Anti-inflammatory Therapy Following Selective Laser Trabeculoplasty (SLT): A Randomized, Masked, Placebo Controlled Study

  • Phase

    N/A

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Study Participants

    120
The type of anti-inflammatory medication used post selective laser trabeculoplasty (SLT) may have an impact on the intra-ocular pressure (IOP) lowering effect of SLT. This study will evaluate the IOP lowering effect of SLT following the topical administration of one of the following: prednisolone 1%, ketorolac 0.5% or artificial tears.
Patients who have been chosen to undergo SLT for glaucoma will be randomized to receive one of prednisolone 1%, ketorolac 0.5% or artificial tears four times a day for 5 days following administration of the laser treatment. The IOP will be measured at various time points following SLT: 1 hour, 2 days, 1 week, 1 month, 3 months, 6 months, and 1 year.
Study Started
Jan 31
2007
Primary Completion
Jun 30
2009
Study Completion
Dec 31
2014
Last Update
Sep 23
2015
Estimate

Drug prednisolone 1%

eye drop once in each eye treated, 4 times / day for 5 days post-laser

Drug ketorolac 0.5%

eye drop once in each eye treated, 4 times / day for 5 days post-laser

  • Other names: Acular

Drug Artificial Tears (Methyl cellulose drops)

eye drop once in each eye treated, 4 times / day for 5 days post-laser

  • Other names: Refresh Tears

1 Active Comparator

Prednisolone 1% eye drop

2 Active Comparator

ketorolac 0.5% eye drop

3 Placebo Comparator

Artificial Tears (methyl cellulose eye drop)

Criteria 

Inclusion Criteria:

primary open angle glaucoma, pseudo exfoliation glaucoma

Exclusion Criteria:

previous incisional glaucoma surgery
No Results Posted